A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT07174908
Phase
PHASE3
Sponsor
InxMed (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IN10018 in combination with D-1553
  • anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Able and willing to provide informed consent and comply with study requirements
  • Has histologically confirmed locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-squamous NSCLC
  • Aged 18-80 years at the time of consent
  • Has KRAS G12C mutation confirmed by central laboratory

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →